AMINOGLYCOSIDES

Course overview

WHILE AMINOGLYCOSIDES ARE AN OLDER CLASS OF MEDICATION, THEY CONTINUE TO BE CLINICALLY VALUABLE. AMINOGLYCOSIDES HAVE A BROAD SPECTRUM OF ACTIVITY COVERING AEROBIC ORGANISMS, INCLUDING GRAM-NEGATIVE BACTERIA AND MYCOBACTERIA. THERE ARE SEVERAL DRUGS WITHIN THE AMINOGLYCOSIDE CLASS, INCLUDING GENTAMICIN, TOBRAMYCIN, AMIKACIN, NEOMYCIN, PLAZOMICIN, AND STREPTOMYCIN, AND FDA-APPROVED INDICATIONS VARY BETWEEN THE FOR THESE INDIVIDUAL AMINOGLYCOSIDES. THIS ACTIVITY REVIEWS THE INDICATIONS, CONTRAINDICATIONS, MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS (E.G., OFF-LABEL USES, DOSING, PHARMACODYNAMICS, PHARMACOKINETICS, MONITORING, RELEVANT INTERACTIONS) PERTINENT TO MEMBERS OF THE INTERPROFESSIONAL TEAM WHO WISH TO PRESCRIBE AMINOGLYCOSIDES.